Uncategorized
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly
Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients over 84–96 weeks. read more
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia. read more
Pudgy Penguins Coin PENGU Leaps Past Dogecoin, Shiba Inu, Pepe With 93% Weekly Gain
Pudgy Penguins (CRYPTO: PENGU) has surged more than 90% in a week as bullish momentum builds around strong fundamentals, brand utility, and regulatory developments. read more
Salesforce’s AI Moves Could Skyrocket Service Cloud Revenue
Salesforce’s Service Cloud unit is expected to generate $9.7B revenue in 2026, with 8.5% growth rate and potential for 12% in the long run. Analyst praises AI-powered Agentforce and projects $1.7B revenue and 9% CAGR in 5 years. Flexible pricing and cross-selling also contribute to Salesforce’s growth potential. Latest Ratings for CRM Date Firm Action…
Meta Commits ‘Hundreds Of Billions’ To Build Massive AI Clusters In Race For Superintelligence
Meta Platforms Inc. (NASDAQ: META) is ramping up its artificial intelligence infrastructure plans, with CEO Mark Zuckerberg confirming that the company will invest hundreds of billions of dollars into compute resources as it chases superintelligence. read more
Demystifying General Motors: Insights From 9 Analyst Reviews
Latest Ratings for GM Date Firm Action From To Mar 2022 Benchmark Maintains Buy Feb 2022 Nomura Instinet Downgrades Buy Neutral Feb 2022 Morgan Stanley Downgrades Overweight Equal-Weight View More Analyst Ratings for GM View the Latest Analyst Ratings read more
14 Analysts Have This To Say About Fortinet
Latest Ratings for FTNT Date Firm Action From To Feb 2022 Wedbush Maintains Outperform Feb 2022 Wells Fargo Maintains Overweight Feb 2022 Raymond James Maintains Outperform View More Analyst Ratings for FTNT View the Latest Analyst Ratings read more
Rocket Lab (RKLB) Stock Hits New All-Time High As Citi Boosts Price Target
Rocket Lab shares hit a new all-time high in early Monday trading. The stock is being fueled by a price target increase from Citigroup. read more
Nebius Emerges As Neutral AI Cloud Alternative, Deepens Ties With Nvidia, OpenAI, Microsoft: Analyst
Goldman Sachs analyst initiates coverage of Nebius Group with a Buy rating, citing its strong position in the AI Neoclouds market. read more
Wall Street Pauses As Tariff Concerns Rise, Dollar Eyes Third Straight Gain: What’s Moving Markets Monday?
U.S. equities traded sideways on Monday as investor sentiment wavered following President Donald Trump‘s weekend announcement of a sweeping 30% tariff on all imports from the European Union and Mexico, set to take effect August 1. read more